CL2014002282A1 - Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos. - Google Patents

Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.

Info

Publication number: CL2014002282A1
Authority: CL; Chile
Prior art keywords: mmp9; gelatinase; metalloproteinase; pharmaceutical composition; antibodies against
Prior art date: 2012-02-29

Application number

CL2014002282A

Other languages

English (en)

Inventor

Victoria Smith

Scott Mccauley

Original Assignee

Gilead Biologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-29

Filing date

2014-08-28

Publication date

2015-02-20

2014-08-28 Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc

2015-02-20 Publication of CL2014002282A1 publication Critical patent/CL2014002282A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CL2014002282A 2012-02-29 2014-08-28 Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos. CL2014002282A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2012/027160 WO2013130078A1 (en)	2012-02-29	2012-02-29	Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number	Publication Date
CL2014002282A1 true CL2014002282A1 (es)	2015-02-20

Family

ID=45816000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002282A CL2014002282A1 (es)	2012-02-29	2014-08-28	Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.

Country Status (23)

Country	Link
US (4)	US9550836B2 (es)
EP (1)	EP2820048B1 (es)
JP (1)	JP6067756B2 (es)
KR (1)	KR20140130724A (es)
CN (1)	CN104395345A (es)
AP (1)	AP2014007907A0 (es)
AU (4)	AU2012318302C1 (es)
BR (1)	BR112014021477A2 (es)
CA (1)	CA2865530C (es)
CL (1)	CL2014002282A1 (es)
CO (1)	CO7061040A2 (es)
CR (1)	CR20140443A (es)
EA (1)	EA201491575A1 (es)
EC (1)	ECSP14020504A (es)
ES (1)	ES2731441T3 (es)
HK (1)	HK1208036A1 (es)
IN (1)	IN2014DN08011A (es)
MD (1)	MD20140107A2 (es)
MX (1)	MX2014010449A (es)
PH (1)	PH12014501931A1 (es)
SG (1)	SG11201405305PA (es)
WO (1)	WO2013130078A1 (es)
ZA (1)	ZA201406319B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012027721A2 (en)	2010-08-27	2012-03-01	Gilead Biologics, Inc	Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) *	2012-02-29	2015-03-31	Gilead Biologics, Inc.	Anticorpi împotriva metaloproteinazei 9 matriciale
SG11201405305PA (en)	2012-02-29	2014-09-26	Gilead Biologics Inc	Antibodies to matrix metalloproteinase 9
CN106062001A (zh) *	2014-02-27	2016-10-26	吉利德科学公司	基质金属蛋白酶9的抗体及其使用方法
EP2985296A1 (en) *	2014-08-13	2016-02-17	Calypso Biotech SA	Antibodies specific for MMP9
EP2985295A1 (en)	2014-08-13	2016-02-17	Calypso Biotech SA	Antibodies specific for MMP9
CN105037553B (zh) *	2015-08-20	2018-04-17	内蒙古蒙元生物基因科技有限公司	一种能够检测癌症的免疫球蛋白
JP2019513737A (ja)	2016-04-08	2019-05-30	ギリアードサイエンシーズ，インコーポレイテッド	がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
US10326830B1 (en) *	2016-09-02	2019-06-18	Amazon Technologies, Inc.	Multipath tunneling to a service offered at several datacenters
EP3555138A1 (en)	2016-12-16	2019-10-23	Université de Bordeaux	Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US10941178B2 (en)	2017-03-17	2021-03-09	Gilead Sciences, Inc.	Method of purifying an antibody
KR102657653B1 (ko)	2017-07-18	2024-04-16	다이이찌 산쿄 가부시키가이샤	활성형 mmp-9 결합 펩티드
CN110885375B (zh) *	2019-12-20	2021-07-02	南京融捷康生物科技有限公司	特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) *	2020-06-12	2022-04-05	浙江工业大学	一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) *	2023-07-12	2024-03-12	北京达成生物科技有限公司	结合mmp3蛋白的双特异性抗体及其用途
EP4788430A1 (en)	2023-10-05	2026-08-12	Ashibio, Inc.	Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en)	1990-10-19	1990-12-05	Cortecs Ltd	Pharmaceutical formulations
DE69233528T2 (de)	1991-11-25	2006-03-16	Enzon, Inc.	Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ES2327812T3 (es) *	1999-07-13	2009-11-04	University Of Southern California	Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
CN1459505A (zh) *	2002-05-21	2003-12-03	赵平	中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用
EP1545611B1 (en) *	2002-09-06	2016-11-09	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
WO2007094842A2 (en) *	2005-12-02	2007-08-23	Genentech, Inc.	Binding polypeptides and uses thereof
PE20090765A1 (es) *	2007-06-08	2009-07-10	Irm Llc	Metodos y composiciones para inducir la apoptosis en celulas cancerosas
US8013125B2 (en) *	2008-03-03	2011-09-06	Dyax Corp.	Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) *	2008-03-03	2011-06-16	ダイアックスコーポレーション	メタロプロテアーゼ９結合タンパク質
WO2010048432A1 (en) *	2008-10-22	2010-04-29	Dyax Corp.	Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010059543A1 (en) *	2008-11-20	2010-05-27	Merck Sharp & Dohme Corp.	Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
CN102822202B (zh) *	2010-01-27	2015-07-22	耶达研究及发展有限公司	抑制金属蛋白的抗体
WO2012027721A2 (en)	2010-08-27	2012-03-01	Gilead Biologics, Inc	Antibodies to matrix metalloproteinase 9
SG11201405305PA (en)	2012-02-29	2014-09-26	Gilead Biologics Inc	Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro)	2012-02-29	2015-03-31	Gilead Biologics, Inc.	Anticorpi împotriva metaloproteinazei 9 matriciale

2012
- 2012-02-29 SG SG11201405305PA patent/SG11201405305PA/en unknown
- 2012-02-29 EP EP12708473.9A patent/EP2820048B1/en active Active
- 2012-02-29 MX MX2014010449A patent/MX2014010449A/es unknown
- 2012-02-29 CN CN201280072749.6A patent/CN104395345A/zh active Pending
- 2012-02-29 ES ES12708473T patent/ES2731441T3/es active Active
- 2012-02-29 MD MDA20140107A patent/MD20140107A2/ro not_active Application Discontinuation
- 2012-02-29 KR KR1020147026786A patent/KR20140130724A/ko not_active Ceased
- 2012-02-29 AU AU2012318302A patent/AU2012318302C1/en not_active Ceased
- 2012-02-29 EA EA201491575A patent/EA201491575A1/ru unknown
- 2012-02-29 HK HK15108571.3A patent/HK1208036A1/xx unknown
- 2012-02-29 US US14/382,301 patent/US9550836B2/en active Active
- 2012-02-29 BR BR112014021477A patent/BR112014021477A2/pt not_active IP Right Cessation
- 2012-02-29 CA CA2865530A patent/CA2865530C/en not_active Expired - Fee Related
- 2012-02-29 AP AP2014007907A patent/AP2014007907A0/xx unknown
- 2012-02-29 IN IN8011DEN2014 patent/IN2014DN08011A/en unknown
- 2012-02-29 WO PCT/US2012/027160 patent/WO2013130078A1/en not_active Ceased
- 2012-02-29 JP JP2014559872A patent/JP6067756B2/ja not_active Expired - Fee Related
2014
- 2014-08-27 PH PH12014501931A patent/PH12014501931A1/en unknown
- 2014-08-27 ZA ZA2014/06319A patent/ZA201406319B/en unknown
- 2014-08-28 CL CL2014002282A patent/CL2014002282A1/es unknown
- 2014-08-29 CO CO14190943A patent/CO7061040A2/es unknown
- 2014-09-24 CR CR20140443A patent/CR20140443A/es unknown
- 2014-09-26 EC ECIEPI201420504A patent/ECSP14020504A/es unknown
2015
- 2015-10-13 AU AU2015242967A patent/AU2015242967B2/en not_active Ceased
2016
- 2016-12-12 US US15/376,232 patent/US20170183421A1/en not_active Abandoned
2017
- 2017-08-16 AU AU2017216508A patent/AU2017216508B2/en not_active Ceased
- 2017-11-17 AU AU2017261626A patent/AU2017261626A1/en not_active Abandoned
2019
- 2019-01-10 US US16/245,169 patent/US10800857B2/en active Active
2020
- 2020-09-10 US US17/017,491 patent/US11634505B2/en active Active

Also Published As

Publication number	Publication date
AU2015242967A1 (en)	2015-11-05
JP2015514394A (ja)	2015-05-21
AU2012318302C1 (en)	2017-06-15
AU2017261626A1 (en)	2017-12-07
HK1208036A1 (en)	2016-02-19
EA201491575A1 (ru)	2015-01-30
CO7061040A2 (es)	2014-09-19
EP2820048B1 (en)	2019-04-17
AU2012318302B2 (en)	2016-08-18
MD20140107A2 (ro)	2015-03-31
CN104395345A (zh)	2015-03-04
WO2013130078A1 (en)	2013-09-06
AU2017216508A1 (en)	2017-08-31
IN2014DN08011A (es)	2015-05-01
US10800857B2 (en)	2020-10-13
MX2014010449A (es)	2015-02-10
SG11201405305PA (en)	2014-09-26
CA2865530C (en)	2019-02-19
AU2017216508B2 (en)	2019-03-07
AU2015242967B2 (en)	2017-08-24
ECSP14020504A (es)	2015-09-30
BR112014021477A2 (pt)	2018-06-12
US20210054101A1 (en)	2021-02-25
NZ629888A (en)	2017-02-24
US20170183421A1 (en)	2017-06-29
CR20140443A (es)	2014-11-17
US11634505B2 (en)	2023-04-25
EP2820048A1 (en)	2015-01-07
ZA201406319B (en)	2016-02-24
HK1205153A1 (en)	2015-12-11
US20150140580A1 (en)	2015-05-21
US9550836B2 (en)	2017-01-24
AU2012318302A1 (en)	2013-09-19
CA2865530A1 (en)	2013-09-06
PH12014501931A1 (en)	2014-11-24
ES2731441T3 (es)	2019-11-15
AP2014007907A0 (en)	2014-08-31
US20190127486A1 (en)	2019-05-02
KR20140130724A (ko)	2014-11-11
JP6067756B2 (ja)	2017-01-25

Publication	Publication Date	Title
CL2014002258A1 (es)	2015-02-20	Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
CL2014002954A1 (es)	2015-02-06	Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
CL2014003136A1 (es)	2015-02-27	Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2015001486A1 (es)	2015-10-16	Composición que comprende agentes de control biológico.
CL2014001930A1 (es)	2014-10-03	Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2016002772A1 (es)	2017-06-09	Composiciones de insulina de rápida acción
BR112015020743A2 (pt)	2017-09-26	cápsula de dose individual e sistema.
CL2014002616A1 (es)	2015-01-30	Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
CL2014002019A1 (es)	2015-01-16	Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2014002493A1 (es)	2015-02-06	Polipeptidos de relaxina modificados; composicion que lo contiene y sus usos (div. sol. 475-2013)
EP3661489A4 (en)	2021-08-04	COMPOSITION OF FLOTTABLE PHARMACEUTICAL MICROCAPSULE
EP3436040A4 (en)	2019-12-11	COMPOSITIONS WITH TANNERIC ACIDS AND USES THEREOF
CL2014003148A1 (es)	2015-02-27	Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112015006910A2 (pt)	2017-07-04	aparelho hidráulico que apresenta uma estrutura melhorada para sua cilindrada.
EP3364958A4 (en)	2019-08-28	MODULATORS OF SESTRINE-GATOR2 INTERACTION AND USES THEREOF
EP2812091A4 (en)	2015-07-01	CHROMATOGRAPHY MEDIA AND DEVICES
CL2014003135A1 (es)	2015-01-09	Formulacion que comprende un quelato de oligonucleotidos; y sus usos.
IL250112B (en)	2022-10-01	Aqueous formulation comprising paracetamol and ibuprofen
CL2016001313A1 (es)	2017-01-20	Formulaciones listas de fertilizante líquido de bifentrina.
MX343035B (es)	2016-10-21	Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
EP2490543A4 (en)	2013-02-06	EXTRACTS, FRACTIONS AND COMPOSITIONS WITH ACETOGENINES AND ITS APPLICATION
CR20150603A (es)	2016-04-04	Metaloproteinasa de la matriz y usos del mismo
CL2014002204A1 (es)	2015-01-30	Formulacion de anticuerpo anti il-17 y sus usos.
CL2014003495A1 (es)	2015-04-10	Agentes herbicidas que contienen flufenacet.
EP3003344A4 (en)	2016-12-28	CONOTOXINPEPTIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF